SARS-CoV-2 controlled kinase functions | Pandemic PACT Tracker

Key facts

Disease
COVID-19
Start & end year
2021
2024
Known Financial Commitments (USD)
$475,969.07
Funder
FWF
Principal Investigator
N/A
Research Location
Austria
Lead Research Institution
Institut für Biochemie, Universität Innsbruck
Research Priority Alignment
N/A

Research Category
Clinical characterisation and management
Research Subcategory
Disease pathogenesis
Special Interest Tags
N/A
Study Type
Unspecified
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable

Abstract

Publicationslinked via Europe PMC

Last Updated:an hour ago

View all publications at Europe PMC

Phosphorylation of the compartmentalized PKA substrate TAF15 regulates RNA-protein interactions.

Direct comparison of SARS-CoV-2 variant specific neutralizing antibodies in human and hamster sera.

Characterizing SARS-CoV-2 neutralization profiles after bivalent boosting using antigenic cartography.

Disruptor: Computational identification of oncogenic mutants disrupting protein-protein and protein-DNA interactions.

Missense variant interaction scanning reveals a critical role of the FERM domain for tumor suppressor protein NF2 conformation and function.

Tracking and blocking interdependencies of cellular BRAF-MEK oncokinase activities.

BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants.

Kinase perturbations redirect mitochondrial function in cancer.

Physiological Cell Culture Media Tune Mitochondrial Bioenergetics and Drug Sensitivity in Cancer Cell Models.